The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted not to recommend the use of brexpiprazole in combination with sertraline for the treatment of posttraumatic stress disorder (PTSD).
The US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted not to recommend the use of brexpiprazole in combination with sertraline for the treatment of posttraumatic stress disorder (PTSD).
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
A randomized clinical trial published in JAMA Psychiatry found that oral semaglutide may improve effort-based decision-making in adults with major depressive disorder (MDD).
A randomized clinical trial published in JAMA Psychiatry found that oral semaglutide may improve effort-based decision-making in adults with major depressive disorder (MDD).
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
Active navigated transcranial magnetic stimulation (TMS) added to intensive residential treatment was associated with greater reduction of symptoms in patients with combat-related posttraumatic stress disorder (PTSD) than sham TMS.
Active navigated transcranial magnetic stimulation (TMS) added to intensive residential treatment was associated with greater reduction of symptoms in patients with combat-related posttraumatic stress disorder (PTSD) than sham TMS.
A systematic review published in Frontiers in Psychiatry reports that algorithm-guided treatment (AGT) is generally associated with improved remission rates and more timely treatment modifications compared with treatment as usual (TAU).
A systematic review published in Frontiers in Psychiatry reports that algorithm-guided treatment (AGT) is generally associated with improved remission rates and more timely treatment modifications compared with treatment as usual (TAU).
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Neurocrine Biosciences reported new real-world evidence demonstrating higher treatment persistence with valbenazine (Ingrezza) compared with deutetrabenazine (Austedo XR) among adults with tardive dyskinesia (TD).
Attention-deficit/hyperactivity disorder (ADHD) diagnosis rates in people younger than 30 years in British Columbia, Canada, rose steadily from 2003 to 2023 and appeared to accelerate after both DSM-5 implementation and the COVID-19 pandemic.
Attention-deficit/hyperactivity disorder (ADHD) diagnosis rates in people younger than 30 years in British Columbia, Canada, rose steadily from 2003 to 2023 and appeared to accelerate after both DSM-5 implementation and the COVID-19 pandemic.
Bipolar II disorder (BD-II) is associated with significantly increased mortality, according to a large population-based cohort study published in JAMA Network Open.
Bipolar II disorder (BD-II) is associated with significantly increased mortality, according to a large population-based cohort study published in JAMA Network Open.
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
Interim results from a phase 2 randomized, double-blind, placebo-controlled trial of tazbentetol demonstrated early signals of efficacy across schizophrenia symptom domains.
Interim results from a phase 2 randomized, double-blind, placebo-controlled trial of tazbentetol demonstrated early signals of efficacy across schizophrenia symptom domains.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Psych Congress Steering Committee member Brooke Kempf, PMHNP-BC, offers clinicians a practical framework for differentiating overlapping symptoms, anxious distress, and mixed features in MDD.
Psych Congress Steering Committee member Brooke Kempf, PMHNP-BC, offers clinicians a practical framework for differentiating overlapping symptoms, anxious distress, and mixed features in MDD.
Psych Congress Steering Committee Partner Philip Gehrman, PhD, CBSM, FAASM, discusses how targeting sleep may improve outcomes for patients with co-occurring sleep and psychiatric disorders.
Psych Congress Steering Committee Partner Philip Gehrman, PhD, CBSM, FAASM, discusses how targeting sleep may improve outcomes for patients with co-occurring sleep and psychiatric disorders.
Timothy Wilens, MD, explores common patterns of attention-deficit/hyperactivity disorder (ADHD) psychiatric comorbidities throughout different developmental stages.
Timothy Wilens, MD, explores common patterns of attention-deficit/hyperactivity disorder (ADHD) psychiatric comorbidities throughout different developmental stages.
In this insightful discussion, Brittany Albright, MD, MPH, Co-Chair, Psych Congress Elevate, offers a comprehensive overview of the role that deprescribing plays in effective psychiatric care.
In this insightful discussion, Brittany Albright, MD, MPH, Co-Chair, Psych Congress Elevate, offers a comprehensive overview of the role that deprescribing plays in effective psychiatric care.
Chelsie Monroe, APN, PMHNP-BC, discusses practical screening strategies, including the use of the Epworth Sleepiness Scale, the importance of collaboration with sleep specialists, and the clinical relevance of the orexin system.
Chelsie Monroe, APN, PMHNP-BC, discusses practical screening strategies, including the use of the Epworth Sleepiness Scale, the importance of collaboration with sleep specialists, and the clinical relevance of the orexin system.
In this video, Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, offers several practical considerations for mental health care providers contemplating the use of AI in psychiatric practice.
In this video, Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, offers several practical considerations for mental health care providers contemplating the use of AI in psychiatric practice.
Edward Kaftarian, MD, Steering Committee, Psych Congress, provides an update on the current state of HIPAA requirements for clinicians practicing via telehealth.
Edward Kaftarian, MD, Steering Committee, Psych Congress, provides an update on the current state of HIPAA requirements for clinicians practicing via telehealth.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
How familiar are you with DTx for the treatment of attention-deficit/hyperactivity disorder? Test your knowledge with this short, multiple-choice quiz.
How familiar are you with DTx for the treatment of attention-deficit/hyperactivity disorder? Test your knowledge with this short, multiple-choice quiz.
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
